Literature DB >> 24173823

Increased metastatic potential of residual carcinoma after transarterial embolization in rat with McA-RH7777 hepatoma.

Guang-Zhi Wang1, Zhu-Ting Fang, Wei Zhang, Xu-Dong Qu, Sheng Qian, Rong Liu, Jian-Hua Wang.   

Abstract

Transarterial chemoembolization represents a first-line non-curative therapy for hepatocellular carcinoma (HCC), although the biological changes in the remaining cancer after embolization are not completely understood. In the present study, we examined whether transarterial embolization (TAE) enhances the metastatic potential of residual HCC and investigated the mechanisms underlying embolization. The hepatoma cell line McA-RH7777, which is marked by green fluorescent protein (GFP), was used in the study. The invasion of cells cultured under hypoxia and normoxia was observed using the Transwell assay. Twenty male buffalo rats were implanted with GFP transfected McA-RH7777 tumors in the left lateral lobe of the liver. After laparotomy and retrograde placement of a catheter into the gastroduodenal artery (on the 14th day after implantation), TAE using lipiodol (0.2 ml/kg) was performed. Tumor volumes were measured before and after treatment using magnetic resonance imaging (MRI). Lung metastases were observed using fluorescence imaging, and the molecular changes of residual tumor cells were evaluated by western blotting or immunohistochemistry. The invasion assays indicated that the number of invading hypoxic cells was significantly higher than that of normoxic cells (30.2 ± 2.46 vs. 20.4 ± 1.89, P=0.013). Accompanying an increase in hypoxia-inducible factor-1α (HIF-1α) expression, the metastatic potential of tumor cells following hypoxia or TAE was enhanced. This enhanced metastatic potential was indicated by a significant reduction in the expression of E-cadherin and an upregulation of N-cadherin and vimentin expression. The number of lung metastases in the TAE group was 19.20 ± 1.76, whereas this number was 11.30 ± 1.54 in the control group, which represented a statistically significant difference (P=0.003). In conclusion, hypoxia in the residual tumor after TAE can increase the invasiveness and metastatic potential of HCC and may be responsible for the failure of TAE.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24173823     DOI: 10.3892/or.2013.2820

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.

Authors:  Guang-Zhi Wang; Wei Zhang; Zhu-Ting Fang; Wen Zhang; Min-Jie Yang; Guo-Wei Yang; Shuo Li; Lian Zhu; Li-Li Wang; Wei-Sheng Zhang; Rong Liu; Sheng Qian; Jian-Hua Wang; Xu-Dong Qu
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-23       Impact factor: 4.553

2.  Rapid Intrahepatic Progression of Hepatocellular Carcinoma after Transarterial Chemoembolization: A Case Report.

Authors:  Tanveer H Siraj; Asim Tameez Ud Din; Farooq Mohyud Din Chaudhary; Sultan Ahmad; Khaleeq H Siddiqui
Journal:  Cureus       Date:  2019-08-02

3.  Synergistic effects of arsenic trioxide combined with Salmonella typhimurium in treating the advanced hepatocellular carcinoma in rat models.

Authors:  Qing Zhao; Ying Wang; Wen-Tao Li
Journal:  J Gastrointest Oncol       Date:  2021-08

4.  Impact of Histotripsy on Development of Intrahepatic Metastases in a Rodent Liver Tumor Model.

Authors:  Tejaswi Worlikar; Man Zhang; Anutosh Ganguly; Timothy L Hall; Jiaqi Shi; Lili Zhao; Fred T Lee; Mishal Mendiratta-Lala; Clifford S Cho; Zhen Xu
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.639

5.  Melittin Inhibits Hypoxia-Induced Vasculogenic Mimicry Formation and Epithelial-Mesenchymal Transition through Suppression of HIF-1α/Akt Pathway in Liver Cancer.

Authors:  Qunwei Chen; Wanfu Lin; Zifei Yin; Yong Zou; Shufang Liang; Shanming Ruan; Peifeng Chen; Shu Li; Qijin Shu; Binbin Cheng; Changquan Ling
Journal:  Evid Based Complement Alternat Med       Date:  2019-04-01       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.